Neurosense Therapeutics Ltd Cash Flow-to-Debt Ratio
Neurosense Therapeutics Ltd cash flow-to-debt ratio. Neurosense Therapeutics Ltd (NRSN) has a Cash Flow-to-Debt Ratio of -0.71x as of December 2025, meaning its operating cash flow of $-1.84 Million could theoretically repay -1% of its total liabilities ($2.59 Million) in one year. See NRSN free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Neurosense Therapeutics Ltd (2019–2025)
Cash flow-to-debt ratio of Neurosense Therapeutics Ltd from 2019 to 2025. Historical debt coverage capacity for Neurosense Therapeutics Ltd across 7 annual periods. Check Neurosense Therapeutics Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Neurosense Therapeutics Ltd Cash Flow-to-Debt Ratio by Year (2019–2025)
Neurosense Therapeutics Ltd cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Neurosense Therapeutics Ltd. For the full cash flow conversion analysis, see Neurosense Therapeutics Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.96x | $-7.67 Million | $2.59 Million | ▲ +41.7% |
| 2024 | -5.09x | $-10.13 Million | $1.99 Million | ▼ -201.1% |
| 2023 | -1.69x | $-8.35 Million | $4.94 Million | ▲ +53.4% |
| 2022 | -3.63x | $-7.59 Million | $2.09 Million | ▼ -471.7% |
| 2021 | -0.63x | $-1.54 Million | $2.42 Million | ▲ +89.0% |
| 2020 | -5.79x | $-695.00K | $120.00K | ▲ +63.2% |
| 2019 | -15.73x | $-582.00K | $37.00K | — |